Vamorolone, an innovative designer steroid for Duchenne Muscular Dystrophy, has reached a critical stage in the drug development process.
Through the VISION-DMD project, 18 international clinical trial sites are now open across 6 countries, undertaking a Phase 2b study to evaluate the safety and efficacy of vamorolone in comparison with prednisone and placebo. More trial site countries will open across Europe in the coming months with the goal to recruit 120 Duchenne boys aged 4-7 years. Vamorolone, a liquid suspension developed by ReveraGen Biopharma, is expected to have the benefits of steroids with significantly fewer side effects. Steroids are the standard of care for Duchenne enabling boys to walk for longer, but side effects limit their long-term use.